The ipa peptide (Ipamorelin) represents one of the most selective growth hormone secretagogues evaluated in modern peptide research. Designed for rigorous in vitro and animal model studies, this pentapeptide provides researchers with a unique tool for investigating pituitary somatotroph pathways without confounding endocrine spikes. PX1 Research supplies high-purity ipa peptide verified via analytical RP-HPLC and mass spectrometry for consistent laboratory reproducibility.
The ipa peptide (Ipamorelin) represents one of the most selective growth hormone secretagogues evaluated in modern peptide research. Designed for rigorous in vitro and animal model studies, this pentapeptide provides researchers with a unique tool for investigating pituitary somatotroph pathways without confounding endocrine spikes. PX1 Research supplies high-purity ipa peptide verified via analytical RP-HPLC and mass spectrometry for consistent laboratory reproducibility.
The ipa peptide (Ipamorelin) is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively binds to the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth hormone release in preclinical models without elevating cortisol, adrenocorticotropic hormone (ACTH), or prolactin levels. It is supplied exclusively as a research compound for in vitro and laboratory experimentation.
Originally synthesized to overcome the off-target endocrine stimulation characteristic of early-generation ghrelin mimetics, the ipa peptide sequence (Aib-His-D-2Nal-D-Phe-Lys-NH2) incorporates unnatural amino acids that grant enhanced enzymatic resistance. In comparative bioassays, it has demonstrated a distinct receptor activation profile, rendering it a benchmark molecule in cell signaling, pituitary physiology, and metabolic regulatory studies.
Investigators utilize the ipa peptide to explore growth hormone secretagogue receptor signaling, somatotroph responsiveness under altered metabolic conditions, and the downstream genomic effects of endogenous GH spikes. All material provided by PX1 Research is intended strictly for qualified laboratory environments and non-clinical research applications.
The primary structure of the ipa peptide comprises five amino acid residues, including specialized D-amino acids and alpha-aminobutyric acid (Aib). This structural modification confers significant protection against cleavage by serine proteases and peptidases present in culture media and biological samples.
With a molecular formula of C38H49N9O5 and a molecular weight of approximately 711.85 g/mol, the molecule exhibits strong water solubility when lyophilized as a trifluoroacetate (TFA) or acetate salt. Understanding its chemical stability under varying pH and temperature conditions is essential for maintaining experimental fidelity during multi-day assays.
Researchers evaluating compounds across the PX1 Research catalog rely on detailed chemical specifications. Below is a summary of the baseline biochemical properties of the ipa peptide:
The primary mechanism of action for the ipa peptide centers on its high-affinity binding to the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a G-protein coupled receptor (GPCR) expressed predominantly in the anterior pituitary gland and hypothalamus. Receptor binding assays demonstrate that ipa activates the phospholipase C (PLC) pathway, triggering intracellular inositol trisphosphate (IP3) accumulation and calcium ion mobilization.
Unlike endogenous ghrelin or non-selective ghrelin mimetics, the ipa peptide exhibits minimal binding affinity for secondary neuroendocrine receptors. Preclinical binding studies confirm that its activation of GHS-R1a does not stimulate the hypothalamic-pituitary-adrenal (HPA) axis, thereby avoiding the non-specific release of stress hormones.
This receptor selectivity makes the ipa peptide an ideal tool for isolated somatotroph signaling studies where secondary hormone interactions could obscure primary metabolic or cellular end-points. Detailed investigation into these pathways can be found within our expanded research library.
In vivo rodent models and primary pituitary cell culture studies consistently show that the ipa peptide induces dose-dependent growth hormone release. Notably, early preclinical investigations established that the peak amplitude of GH release induced by ipa matches that of traditional secretagogues, while maintaining a baseline level for ACTH and cortisol identical to vehicle controls.
Longitudinal animal studies indicate that repeated administration of the ipa peptide preserves natural pulsatile GH patterns rather than inducing static, tonic elevations. This preservation of physiological pulsatilities is crucial for preclinical studies investigating receptor desensitization and down-regulation kinetics over extended observation windows.
Furthermore, tissue culture models reveal that somatotroph cells exposed to ipa display robust signal transduction even after pre-treatment with competitive inhibitors, highlighting the ligand's high functional efficacy at the GHS-R1a locus.
When designing comparative secretagogue studies, researchers frequently evaluate the ipa peptide alongside earlier GHS molecules. Key differences exist in receptor selectivity, appetite stimulation pathways, and off-target hormone activity.
Legacy compounds such as GHRP-6 and GHRP-2 demonstrate potent GH release but frequently trigger significant elevations in plasma cortisol and prolactin. Additionally, GHRP-6 strongly stimulates hypothalamic orexigenic pathways, inducing hyperphagia in animal models. Conversely, Hexarelin exhibits powerful secretagogue activity but causes rapid receptor desensitization upon repeated exposure.
In contrast, the ipa peptide exhibits minimal orexigenic receptor activation and negligible cortisol or prolactin release. This high selectivity profile allows researchers to isolate GH-driven cellular mechanisms without the confounding variables introduced by secondary endocrine activation. For broad comparative studies across the class, refer to our overview of growth hormone secretagogues.
A prominent area of investigation in peptide biochemistry involves dual-receptor activation of the pituitary somatotroph. Growth hormone release is naturally regulated by two distinct pathways: Growth Hormone-Releasing Hormone (GHRH) acting via GHRH receptors, and Ghrelin acting via GHS-R1a.
Preclinical data indicate that simultaneous stimulation of both receptor classes produces a synergistic, rather than additive, GH release response. When the ipa peptide is co-administered in vitro or in animal models with GHRH agonists such as CJC-1295 No DAC, intracellular cyclic AMP (cAMP) and calcium signaling pathways are activated concurrently.
Laboratories examining high-yield secretagogue dynamics frequently utilize standardized ipamorelin product formulations to map these intracellular crosstalk mechanisms and evaluate receptor desensitization thresholds under dual-agonist conditions.
Beyond pituitary hormone dynamics, preclinical studies have evaluated the systemic downstream effects of ipa peptide administration in animal models of bone density, muscle wasting, and metabolic regulation.
In rodent models of osteopenia, treatment with ipa peptide demonstrated increased longitudinal bone growth, enhanced trabecular bone mineral density, and elevated markers of osteoblast activity. These findings suggest that downstream IGF-1 induction plays a direct role in osteoblast differentiation and extracellular matrix mineralization.
In muscle tissue assays, preclinical research indicates that GHS-R1a activation by ipa may attenuate protein degradation pathways (such as the ubiquitin-proteasome system) in denervation or corticosteroid-induced atrophy models. Researchers continue to explore these cellular pathways to understand the broader structural impact of ghrelin receptor selective agonism.
To ensure experimental validity, proper handling, reconstitution, and storage of the ipa peptide are critical. Lyophilized peptide powder should be stored at -20°C upon receipt for short-term stability, or at -80°C for long-term storage, protected from light and moisture.
Reconstitution should be performed in a certified laminar flow hood using sterile, laboratory-grade solvents such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile Water for Injection (WFI). The diluent should be gently trickled down the inner glass wall of the vial, followed by gentle swirling. Vortexing must be strictly avoided, as mechanical shear forces can cause peptide denaturation or aggregation.
Once reconstituted, stock solutions should be aliquoted into single-use polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles. Reconstituted solutions are typically stable for up to 30 days when maintained at 2°C to 8°C.
The validity of preclinical research relies entirely on the purity and identity of the chemical compounds evaluated. Unidentified peptide fragments, residual solvents, or bacterial endotoxins can invalidate cell culture assays and confound in vivo telemetry.
PX1 Research enforces strict quality control standards for every lot of ipa peptide. Quality assurance includes double-testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity (>98%) and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) to confirm molecular weight and exact sequence identity.
Furthermore, our compounds undergo rigorous bacterial endotoxin testing using Chromogenic LAL Assays to ensure endotoxin levels remain below strictly enforced thresholds (<0.5 EU/mg). Academic institutions and commercial facilities sourcing through our wholesale laboratory accounts receive full access to lot-specific, third-party Certificates of Analysis (COAs).
When purchasing compounds for controlled laboratory experiments, selecting a dependable USA-based supplier is vital for maintaining chain-of-custody and lot-to-lot consistency. PX1 Research operates out of ISO 17025 accredited and GMP-compliant facilities located in California and Arizona.
We guarantee same-day shipping for orders placed before standard cutoff times, ensuring temperature-sensitive compounds spend minimal time in transit. Every batch of ipa peptide is protected in vacuum-sealed vials with tamper-evident packaging to safeguard integrity from our lab to yours.
Explore our complete range of high-purity research peptides to equip your laboratory with fully verified, analytical-grade research compounds.
What is the primary receptor target of the ipa peptide?
The ipa peptide selectively targets and activates the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a G-protein coupled receptor located primarily in the anterior pituitary and hypothalamus.
How does ipa peptide differ from legacy secretagogues like GHRP-2 or GHRP-6?
Unlike GHRP-2 and GHRP-6, the ipa peptide does not induce significant elevations in cortisol, ACTH, or prolactin, nor does it strongly stimulate appetite via orexigenic pathways. It offers significantly higher receptor selectivity.
What purity level is guaranteed for PX1 Research ipa peptide?
Every lot of ipa peptide from PX1 Research is verified via RP-HPLC to achieve a minimum purity of 98%, backed by lot-specific third-party COAs including mass spectrometry data.
What are the recommended storage conditions for lyophilized ipa peptide?
Lyophilized ipa peptide should be stored at -20°C for short-term preservation or -80°C for extended long-term storage, protected from light and desiccated.
How should ipa peptide be reconstituted for laboratory use?
Reconstitution should be conducted in a sterile environment using Bacteriostatic Water or sterile WFI. Solvent should be added down the side of the vial and gently swirled without vortexing.
Are PX1 Research compounds tested for endotoxins?
Yes, all peptide batches undergo Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin content remains strictly below 0.5 EU/mg, protecting sensitive in vitro and in vivo models.
Can ipa peptide be co-administered with GHRH analogs in research protocols?
Yes, preclinical studies frequently evaluate the co-administration of ipa peptide with GHRH agonists like CJC-1295 to study dual-receptor synergy and non-competitive GH release pathways.
Where are PX1 Research compounds manufactured and shipped from?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.